Drug Overview Natrecor (nesiritide; Johnson&Johnson) is a recombinant form of human brain natriuretic peptide (BNP), a circulating hormone of cardiac origin indicated for the treatment of patients with acute decompensated heartf failure (ADHF) who have dyspnea at rest or with minimal activity.
BNP is naturally secreted by the ventricular myocardium in response to volume overload and increased filling pressure. It binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3’5’-cyclic monophosphate (cGMP) and smooth muscle cell relaxation. cGMP serves as a second messenger to dilate veins and arteries, and Natrecor causes natriuresis and a reduction in intravascular volume. The natriuretic effect results from a direct inhibition of sodium absorption in the renal collecting duct, increased glomerular infiltration, and inhibited aldosterone production and secretion. This produces a prompt fall in systemic vascular resistance and pulmonary capillary wedge pressure, associated with rapid clinical improvement in ADHF.
Our reports have been used by over 10K customers, including:
“Vasomotor symptoms – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Vasomotor symptoms pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...
“Mitogen Activated Protein Kinase Kinase 2 inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mitogen Activated Protein Kinase Kinase 2 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers...
“Uterine fibroids – Pipeline Insight, 2020,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Uterine fibroids pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...
‘Acromegaly-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Acromegaly market report provides...
Acromegaly and Gigantism - Global Drug Forecast and Market Analysis to 2029
Summary
Acromegaly and gigantism are rare disorders of the pituitary gland characterized by the hypersecretion of growth hormone (GH).This GH excess is often a result of a benign GH-secreting pituitary adenoma.
Rarely,...